Blake Mandell

Chief Executive Officer at Transcend Therapeutics

Health Technology

Profile

Blake Mandell is the founder of Transcend Therapeutics, Inc. (New York).
He held the title of Chief Executive Officer at the company, although he is no longer active in that role.

Blake Mandell active positions

Companies	Position	Start
Transcend Therapeutics Transcend Therapeutics BiotechnologyHealth Technology Transcend Therapeutics is an American biotechnology company that discovers, develops, and delivers next-generation psychoactive medicines to work towards a world where people no longer suffer from neuropsychiatric disease. The company is located in the US. The company focuses on developing medicines that are accessible to a larger percentage of patients in need, specifically the tens of millions of patients who already take psychotropic medication. Transcend Therapeutics has real-world data for its lead compound, TSND-201, demonstrating robust responses in patients with PTSD. As a public benefit corporation, the company has pledged 10% of its founding shares towards nonprofits focused on scientific research and patient access.	Chief Executive Officer	-

All active positions of Blake Mandell

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Blake Mandell's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Transcend Therapeutics Transcend Therapeutics BiotechnologyHealth Technology Transcend Therapeutics is an American biotechnology company that discovers, develops, and delivers next-generation psychoactive medicines to work towards a world where people no longer suffer from neuropsychiatric disease. The company is located in the US. The company focuses on developing medicines that are accessible to a larger percentage of patients in need, specifically the tens of millions of patients who already take psychotropic medication. Transcend Therapeutics has real-world data for its lead compound, TSND-201, demonstrating robust responses in patients with PTSD. As a public benefit corporation, the company has pledged 10% of its founding shares towards nonprofits focused on scientific research and patient access.	Health Technology